These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24166484)

  • 1. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.
    Rodriguez F; Cannon CP; Steg PG; Kumbhani DJ; Goto S; Smith SC; Eagle KA; Ohman EM; Umez-Eronini AA; Hoffman E; Bhatt DL;
    Clin Cardiol; 2013 Dec; 36(12):721-7. PubMed ID: 24166484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to secondary prevention medications and four-year outcomes in outpatients with atherosclerosis.
    Kumbhani DJ; Steg PG; Cannon CP; Eagle KA; Smith SC; Hoffman E; Goto S; Ohman EM; Bhatt DL;
    Am J Med; 2013 Aug; 126(8):693-700.e1. PubMed ID: 23800583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction.
    Shore S; Jones PG; Maddox TM; Bradley SM; Stolker JM; Arnold SV; Parashar S; Peterson P; Bhatt DL; Spertus J; Ho PM
    Heart; 2015 May; 101(10):800-7. PubMed ID: 25801001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of adherence to evidence-based therapy after acute myocardial infarction.
    Hamood H; Hamood R; Green MS; Almog R
    Eur J Prev Cardiol; 2016 Jun; 23(9):975-85. PubMed ID: 26198723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence.
    Bauer T; Gitt AK; Jünger C; Zahn R; Koeth O; Towae F; Schwarz AK; Bestehorn K; Senges J; Zeymer U;
    Eur J Cardiovasc Prev Rehabil; 2010 Oct; 17(5):576-81. PubMed ID: 20351550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary prevention after acute myocardial infarction: drug adherence, treatment goals, and predictors of health lifestyle habits. The BLITZ-4 Registry.
    Urbinati S; Olivari Z; Gonzini L; Savonitto S; Farina R; Del Pinto M; Valbusa A; Fantini G; Mazzoni A; Maggioni AP;
    Eur J Prev Cardiol; 2015 Dec; 22(12):1548-56. PubMed ID: 25452625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal pharmacological treatment and adherence to medication in secondary prevention of cardiovascular events in Spain: Results from the CAPS study.
    Cordero A; Rodriguez Padial L; Batalla A; López Barreiro L; Torres Calvo F; Castellano JM; Ruiz E; Bertomeu-Martínez V;
    Cardiovasc Ther; 2017 Apr; 35(2):. PubMed ID: 27957818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of secondary prevention medications among adults with reduced kidney function.
    Chang TI; Gao L; Brown TM; Safford MM; Judd SE; McClellan WM; Limdi NA; Muntner P; Winkelmayer WC
    Clin J Am Soc Nephrol; 2012 Apr; 7(4):604-11. PubMed ID: 22344513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional and practice variation in adherence to guideline recommendations for secondary and primary prevention among outpatients with atherothrombosis or risk factors in the United States: a report from the REACH Registry.
    Kumar A; Fonarow GC; Eagle KA; Hirsch AT; Califf RM; Alberts MJ; Boden WE; Steg PG; Shao M; Bhatt DL; Cannon CP;
    Crit Pathw Cardiol; 2009 Sep; 8(3):104-11. PubMed ID: 19726929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of medication adherence on clinical outcomes of coronary artery disease: A meta-analysis.
    Du L; Cheng Z; Zhang Y; Li Y; Mei D
    Eur J Prev Cardiol; 2017 Jun; 24(9):962-970. PubMed ID: 28436725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease guideline adherence and self-reported statin use in longstanding type 1 diabetes: results from the Canadian study of longevity in diabetes cohort.
    Bai JW; Boulet G; Halpern EM; Lovblom LE; Eldelekli D; Keenan HA; Brent M; Paul N; Bril V; Cherney DZ; Weisman A; Perkins BA
    Cardiovasc Diabetol; 2016 Jan; 15():14. PubMed ID: 26809442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex Differences in the Use of Statins in Community Practice.
    Nanna MG; Wang TY; Xiang Q; Goldberg AC; Robinson JG; Roger VL; Virani SS; Wilson PWF; Louie MJ; Koren A; Li Z; Peterson ED; Navar AM
    Circ Cardiovasc Qual Outcomes; 2019 Aug; 12(8):e005562. PubMed ID: 31416347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease.
    Adler AJ; Martin N; Mariani J; Tajer CD; Owolabi OO; Free C; Serrano NC; Casas JP; Perel P
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011851. PubMed ID: 28455948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study.
    Gehi AK; Ali S; Na B; Whooley MA
    Arch Intern Med; 2007 Sep; 167(16):1798-803. PubMed ID: 17846400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-related differences in factors associated with the underuse of recommended medications in acute coronary syndrome patients at least one year after hospital discharge.
    Jin H; Tang C; Wei Q; Chen L; Sun Q; Ma G; Liu N
    BMC Cardiovasc Disord; 2014 Sep; 14():127. PubMed ID: 25252927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving patient adherence to secondary prevention medications 6 months after an acute coronary syndrome: observational cohort study.
    Brieger D; Chow C; Gullick J; Hyun K; D'Souza M; Briffa T;
    Intern Med J; 2018 May; 48(5):541-549. PubMed ID: 29345403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of 1-year mortality in patients with contemporary guideline-adherent therapy after acute myocardial infarction: results from the OMEGA study.
    Liosis S; Bauer T; Schiele R; Gohlke H; Gottwik M; Katus H; Sabin G; Zahn R; Schneider S; Rauch B; Senges J; Zeymer U
    Clin Res Cardiol; 2013 Sep; 102(9):671-7. PubMed ID: 23740196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utilization of Evidence-Based Secondary Prevention Medications at the Time of Discharge in Patients with Acute Coronary Syndrome (ACS) in Qatar.
    El-Hajj MS; Saad A; Al-Suwaidi J; Al-Marridi WZ; Elkhalifa DH; Mohamed AA; Mahfoud ZR
    Curr Vasc Pharmacol; 2016; 14(4):394-403. PubMed ID: 26916397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective secondary prevention through cardiac rehabilitation after coronary revascularization and predictors of poor adherence to lifestyle modification and medication. Results of the ICAROS Survey.
    Griffo R; Ambrosetti M; Tramarin R; Fattirolli F; Temporelli PL; Vestri AR; De Feo S; Tavazzi L;
    Int J Cardiol; 2013 Aug; 167(4):1390-5. PubMed ID: 22575623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Impact of Medication Adherence on Long-Term Cardiovascular Outcomes.
    Bansilal S; Castellano JM; Garrido E; Wei HG; Freeman A; Spettell C; Garcia-Alonso F; Lizano I; Arnold RJ; Rajda J; Steinberg G; Fuster V
    J Am Coll Cardiol; 2016 Aug; 68(8):789-801. PubMed ID: 27539170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.